课题基金 / 基金详情

TICIPS: HIV/AIDS, Secondary Infections and Immune Modulation

TICIPS: HIV/AIDS, Secondary Infections and Immune Modulation
TICIPS:HIV/AIDS、继发感染和免疫调节
批准号:
7287874
负责人:
William Robert Folk
金额:
$101.56万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-09-30 至 2009-08-31

项目摘要

项目成果

William Robert Folk的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):估计有469万南非人感染了1型人类免疫缺陷病毒(HIV)。艾滋病毒感染是无法治愈的,如果不治疗,大约95%的感染者最终是致命的。L frutescens被认为是非洲南部传统医学中最有效的植物之一。这种植物已经在当地被用来治疗严重的微生物感染,特别是HIV感染,以及癌症和炎症。有益的效果也被观察到在浪费条件和压力相关的疾病。它可能对艾滋病毒感染的成年人有有益的影响。根据医疗成果研究艾滋病毒健康调查(MOS-HIV)工具,早期艾滋病毒感染与多种族南非人的生活质量显著下降有关。观察到的frutescens的抗炎特性可能有利于影响细胞因子网络,从而对生活质量、病毒复制和免疫功能产生有益影响。重要的是要证明这种广泛使用的植物疗法可以安全地用于艾滋病毒感染的成年人,并试图证明潜在的有益影响。最近的数据表明,Sutherlandia与通常用于治疗艾滋病毒感染的抗逆转录病毒药物之间存在显著的体外相互作用。我们提出了一项为期4年的随机安慰剂对照试验,以确定该植物的安全性及其对生活质量和HIV疾病进展标志物的影响。
英文摘要
DESCRIPTION (provided by applicant): An estimated 4.69 million South Africans are infected with Type 1 human immunodeficiency virus (HIV). HIV infection in incurable and, if untreated, is ultimately fatal in approximately 95% of infected individuals. L frutescens is thought to be among the most efficacious plants used in southern African traditional medicine. The plant has been used in indigenous settings to treat serious microbial infections, especially HIV infection, as well as cancer and inflammatory conditions. Beneficial effects have also been observed in wasting conditions and stress-related disorders. It is possible that L frutescens may have useful effects in HIV infected adults. Early HIV infection has been associated with a significant reduction in quality of life in multiracial South Africans measured by the Medical Outcomes Study HIV Health Survey (MOS-HIV) instrument. The observed anti-inflammatory properties of L. frutescens may favourably influence cytokine networks with beneficial effects on quality of life, viral replication and immune functioning. It is essential to document that this widely used phytotherapy can be used safely in HIV-infected adults, and to attempt to demonstrate potentially beneficial affects. Recent data has demonstrated that there are significant in vitro interactions between Sutherlandia and antiretrovirals commonly used to treat HIV infection. We propose a 4- year randomized placebo controlled trial of Lesssertia frutescens in order to determine this plant species safety and effects on quality of life and markers of HIV disease progression. Specific Aim 1: To determine the safety of Lessertia frutescens used by HIV-1 infected adults. Specific Aim 2: To determine the effect of Lessertia frutescens on quality of life in HIV-infected adults measured by the Medical Outcomes Study HIV Health Survey (MOS-HIV). Specific Aim 3: To assess the influence of Lessertia frutescens on CD4 T-lymphocyte count in HIVinfected adults. Specific Aim 4: To evaluate the impact of Lessertia frutescens on HIV viral load in HIV-infected adults.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Linking Science, Mathematics and Literacy for All Learners
  • 批准号:
    10592425
  • 项目类别:
  • 资助金额:
    $26.12万
  • 财政年份:
    2022
  • 负责人:
    William Robert Folk
  • 依托单位:
Linking Science, Mathematics and Literacy for All Learners
  • 批准号:
    10450437
  • 项目类别:
  • 资助金额:
    $26.88万
  • 财政年份:
    2022
  • 负责人:
    William Robert Folk
  • 依托单位:
Strengthening Middle School Science and Health Education for Diverse Learners by Linking Grade-Level Reading of Complex Texts and Inquiry
  • 批准号:
    9303069
  • 项目类别:
  • 资助金额:
    $26.83万
  • 财政年份:
    2017
  • 负责人:
    William Robert Folk
  • 依托单位:
Strengthening Middle School Science and Health Education for Diverse Learners by Linking Grade-Level Reading of Complex Texts and Inquiry
  • 批准号:
    10252846
  • 项目类别:
  • 资助金额:
    $24.22万
  • 财政年份:
    2017
  • 负责人:
    William Robert Folk
  • 依托单位:
国内基金
海外基金
基于病人旅程地图的HIV/AIDS患者双轨调适策略的混合性研究
基于潜变量增长混合模型的HIV/AIDS患者症状负担发展轨迹研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    胡亚丽
  • 依托单位:
基于RET理论模型下的曼陀罗彩绘疗法在老年HIV/AIDS患者中的心理干预研究
IL-33/NF-κB通路在臭氧暴露致HIV/AIDS患者免疫损伤中的调控机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位: